The MKL1-specific treatment group remained tumour-free, whereas recurrence occurred 8 days after the last treatment with PEI/MKL1/2- or MKL1 + 2-specific siRNAs in one mouse of either group (Fig 6E). This evidence concerns the gene MRTFA and neoplasm.